2012-10-01
The Impact of Extracorporeal Life Support and Hypothermia on Drug Disposition in Critically Ill Infants and Children
Publication
Publication
Pediatric Clinics of North America , Volume 59 - Issue 5 p. 1184- 1204
Extracorporeal membrane oxygenation (ECMO) support is an established lifesaving therapy for potentially reversible respiratory or cardiac failure. In 10% of all pediatric patients receiving ECMO, ECMO therapy is initiated during or after cardiopulmonary resuscitation. Therapeutic hypothermia is frequently used in children after cardiac arrest, despite the lack of randomized controlled trials that show its efficacy. Hypothermia is frequently used in children and neonates during cardiopulmonary bypass (CPB). By combining data from pharmacokinetic studies in children on ECMO and CPB and during hypothermia, this review elucidates the possible effects of hypothermia during ECMO on drug disposition.
| Additional Metadata | |
|---|---|
| , , , , , , , | |
| doi.org/10.1016/j.pcl.2012.07.013, hdl.handle.net/1765/62071 | |
| Pediatric Clinics of North America | |
| Organisation | Department of Pediatrics |
|
Wildschut, E., van Saet, A., Pokorna, P., Ahsman, M., van den Anker, J., & Tibboel, D. (2012). The Impact of Extracorporeal Life Support and Hypothermia on Drug Disposition in Critically Ill Infants and Children. Pediatric Clinics of North America (Vol. 59, pp. 1184–1204). doi:10.1016/j.pcl.2012.07.013 |
|